GSK’s HIV drug beats Gilead market leader in study

( Yahoo )

LONDON (Reuters) – An experimental once-daily AIDS drug from GlaxoSmithKline and its Japanese partner Shionogi proved better than Gilead's market-leading Atripla in a late-stage clinical trial, increasing hopes for the product. Dolutegravir, which could reach the market late next year, belongs to a novel class of drugs known as integrase inhibitors that fight HIV/AIDS by blocking the virus causing the disease from entering cells. It should help British group GSK rejuvenate its HIV/AIDS business – an area it used to dominate but where it has fallen behind rivals, notably U.S.-based Gilead. …

Around The Web

, , , , , , , , , , , , ,

Comments are closed.